Pbkp_redictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen

Review

Abstract: Bevacizumab was the first molecular-targeted antiangiogenic therapy approved for the treatment of me

Palabras claves:

Bevacizumab, Biomarker, Cáncer, colorectal

Autores:

Adrián LLerena, Alonso I., Arroyo G., de Andrés F., Estévez-Carrizo F.E., González-Vacarezza N., Martínez J.

Fuentes:

scopus